FAMCICLOVIR
Generic: FAMCICLOVIR
Basic Information
Manufacturer
Apotex Corp.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
ORAL
FDA Set ID
a5c46194-3692-cd26-0d85-6371974ccc44
Indications & Usage
1 INDICATIONS AND USAGE Famciclovir, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients (1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients (1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir have not been established for: Patients with first episode of genital herpes Patients with ophthalmic zoster Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes 1.1 Immunocompetent Adult Patients Herpes labialis (cold sores) Famciclovir tablets are indicated for the treatment of recurrent herpes labialis in adult patients.
Genital herpes Recurrent episodes Famciclovir tablets are indicated for the treatment of recurrent episodes of genital herpes.
The efficacy of famciclovir tablets when initiated more than 6 hours after onset of symptoms or lesions has not been established.
Suppressive therapy Famciclovir tablets are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in adult patients.
The efficacy and safety of famciclovir tablets for the suppression of recurrent genital herpes beyond 1 year have not been established.
Herpes zoster (shingles) Famciclovir tablets are indicated for the treatment of herpes zoster in adult patients.
The efficacy of famciclovir when initiated more than 72 hours after onset of rash has not been established.
1.2 HIV-Infected Adult Patients Recurrent orolabial or genital herpes Famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected adults.
The efficacy of famciclovir tablets when initiated more than 48 hours after onset of symptoms or lesions has not been established.
Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: Patients with first episode of genital herpes Patients with ophthalmic zoster Immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes
Genital herpes Recurrent episodes Famciclovir tablets are indicated for the treatment of recurrent episodes of genital herpes.
The efficacy of famciclovir tablets when initiated more than 6 hours after onset of symptoms or lesions has not been established.
Suppressive therapy Famciclovir tablets are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in adult patients.
The efficacy and safety of famciclovir tablets for the suppression of recurrent genital herpes beyond 1 year have not been established.
Herpes zoster (shingles) Famciclovir tablets are indicated for the treatment of herpes zoster in adult patients.
The efficacy of famciclovir when initiated more than 72 hours after onset of rash has not been established.
1.2 HIV-Infected Adult Patients Recurrent orolabial or genital herpes Famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected adults.
The efficacy of famciclovir tablets when initiated more than 48 hours after onset of symptoms or lesions has not been established.
Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: Patients with first episode of genital herpes Patients with ophthalmic zoster Immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes
Adverse Reactions
6 ADVERSE REACTIONS Acute renal failure is discussed in greater detail in other sections of the label [see Warnings and Precautions ( 5 )].
The most common adverse events reported in at least 1 indication by greater than 10% of adult patients treated with famciclovir are headache and nausea.
The most common adverse events reported in at least 1 indication by greater than 10% of adult patients are headache and nausea.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Drug Information Service at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1 Clinical Trials Experience in Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Immunocompetent patients The safety of famciclovir has been evaluated in active- and placebo-controlled clinical studies involving 816 famciclovir-treated patients with herpes zoster (famciclovir, 250 mg three times daily to 750 mg three times daily); 163 famciclovir-treated patients with recurrent genital herpes (famciclovir, 1,000 mg twice daily); 1,197 patients with recurrent genital herpes treated with famciclovir as suppressive therapy (125 mg once daily to 250 mg three times daily) of which 570 patients received famciclovir (open-labeled and/or double-blind) for at least 10 months; and 447 famciclovir-treated patients with herpes labialis (famciclovir, 1500 mg once daily or 750 mg twice daily).
Table 2 lists selected adverse events.
Table 2 Selected Adverse Events (all grades and without regard to causality) Reported by greater than or equal to 2% of Patients in Placebo-Controlled Famciclovir Trials* Incidence Event s Herpes Zoster † Recurrent Genital Herpes ‡ Genital Herpes- Suppression § Herpes Labialis ‡ Famciclovir n=(273) % Placebo (n=146) % Famciclovir n=(163) % Placebo (n=166) % Famciclovir (n=458) % Placebo (n=63) % Famciclovir (n=447) % Placebo (n=254) % Nervous System Headache 22.7 17.8 13.5 5.4 39.3 42.9 8.5 6.7 Paresthesia 2.6 0.0 0.0 0.0 0.9 0.0 0.0 0.0 Migraine 0.7 0.7 0.6 0.6 3.1 0.0 0.2 0.0 Gastrointestinal Nausea 12.5 11.6 2.5 3.6 7.2 9.5 2.2 3.9 Diarrhea 7.7 4.8 4.9 1.2 9.0 9.5 1.6 0.8 Vomiting 4.8 3.4 1.2 0.6 3.1 1.6 0.7 0.0 Flatulence 1.5 0.7 0.6 0.0 4.8 1.6 0.2 0.0 Abdominal Pain 1.1 3.4 0.0 1.2 7.9 7.9 0.2 0.4 Body as a Whole Fatigue 4.4 3.4 0.6 0.0 4.8 3.2 1.6 0.4 Skin and Appendages Pruritus 3.7 2.7 0.0 0.6 2.2 0.0 0.0 0.0 Rash 0.4 0.7 0.0 0.0 3.3 1.6 0.0 0.0 Reproductive (Female) Dysmenorrhea 0.0 0.7 1.8 0.6 7.6 6.3 0.4 0.0 *Patients may have entered into more than one clinical trial.
† 7 days of treatment ‡ 1 day of treatment § daily treatment Table 3 lists selected laboratory abnormalities in genital herpes suppression trials.
Table 3 Selected Laboratory Abnormalities in Genital Herpes Suppression Studies * Parameter Famciclovir (n=660) † % Placebo (n=210) † % Anemia (<0.8 x NRL) 0.1 0.0 Leukopenia (<0.75 x NRL) 1.3 0.9 Neutropenia (<0.8 x NRL) 3.2 1.5 AST (SGOT) (>2 x NRH) 2.3 1.2 ALT (SGPT) (>2 x NRH) 3.2 1.5 Total Bilirubin (>1.5 x NRH) 1.9 1.2 Serum Creatinine (>1.5 x NRH) 0.2 0.3 Amylase (>1.5 x NRH) 1.5 1.9 Lipase (>1.5 x NRH) 4.9 4.7 * Percentage of patients with laboratory abnormalities that were increased or decreased from baseline and were outside of specified ranges.
† n values represent the minimum number of patients assessed for each laboratory parameter.
NRH=Normal Range High.
NRL=Normal Range Low.
HIV-infected patients In HIV-infected patients, the most frequently reported adverse events for famciclovir (500 mg twice daily; n=150) and acyclovir (400 mg, 5x/day; n=143), respectively, were headache (17% vs.
15%), nausea (11% vs.
13%), diarrhea (7% vs.
11%), vomiting (5% vs.
4%), fatigue (4% vs.
2%), and abdominal pain (3% vs.
6%).
6.2 Postmarketing Experience The adverse events listed below have been reported during post-approval use of famciclovir tablets.
Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Blood and lymphatic system disorders Thrombocytopenia Hepatobiliary disorders Abnormal liver function tests, cholestatic jaundice Immune system disorders Anaphylactic shock, anaphylactic reaction Nervous system disorders Dizziness, somnolence, seizure Psychiatric disorders Confusion (including delirium, disorientation, and confusional state occurring predominantly in the elderly), hallucinations Skin and subcutaneous tissue disorders Urticaria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema (e.g., face, eyelid, periorbital, and pharyngeal edema), hypersensitivity vasculitis C ardiac disorders Palpitations
The most common adverse events reported in at least 1 indication by greater than 10% of adult patients treated with famciclovir are headache and nausea.
The most common adverse events reported in at least 1 indication by greater than 10% of adult patients are headache and nausea.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Drug Information Service at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1 Clinical Trials Experience in Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Immunocompetent patients The safety of famciclovir has been evaluated in active- and placebo-controlled clinical studies involving 816 famciclovir-treated patients with herpes zoster (famciclovir, 250 mg three times daily to 750 mg three times daily); 163 famciclovir-treated patients with recurrent genital herpes (famciclovir, 1,000 mg twice daily); 1,197 patients with recurrent genital herpes treated with famciclovir as suppressive therapy (125 mg once daily to 250 mg three times daily) of which 570 patients received famciclovir (open-labeled and/or double-blind) for at least 10 months; and 447 famciclovir-treated patients with herpes labialis (famciclovir, 1500 mg once daily or 750 mg twice daily).
Table 2 lists selected adverse events.
Table 2 Selected Adverse Events (all grades and without regard to causality) Reported by greater than or equal to 2% of Patients in Placebo-Controlled Famciclovir Trials* Incidence Event s Herpes Zoster † Recurrent Genital Herpes ‡ Genital Herpes- Suppression § Herpes Labialis ‡ Famciclovir n=(273) % Placebo (n=146) % Famciclovir n=(163) % Placebo (n=166) % Famciclovir (n=458) % Placebo (n=63) % Famciclovir (n=447) % Placebo (n=254) % Nervous System Headache 22.7 17.8 13.5 5.4 39.3 42.9 8.5 6.7 Paresthesia 2.6 0.0 0.0 0.0 0.9 0.0 0.0 0.0 Migraine 0.7 0.7 0.6 0.6 3.1 0.0 0.2 0.0 Gastrointestinal Nausea 12.5 11.6 2.5 3.6 7.2 9.5 2.2 3.9 Diarrhea 7.7 4.8 4.9 1.2 9.0 9.5 1.6 0.8 Vomiting 4.8 3.4 1.2 0.6 3.1 1.6 0.7 0.0 Flatulence 1.5 0.7 0.6 0.0 4.8 1.6 0.2 0.0 Abdominal Pain 1.1 3.4 0.0 1.2 7.9 7.9 0.2 0.4 Body as a Whole Fatigue 4.4 3.4 0.6 0.0 4.8 3.2 1.6 0.4 Skin and Appendages Pruritus 3.7 2.7 0.0 0.6 2.2 0.0 0.0 0.0 Rash 0.4 0.7 0.0 0.0 3.3 1.6 0.0 0.0 Reproductive (Female) Dysmenorrhea 0.0 0.7 1.8 0.6 7.6 6.3 0.4 0.0 *Patients may have entered into more than one clinical trial.
† 7 days of treatment ‡ 1 day of treatment § daily treatment Table 3 lists selected laboratory abnormalities in genital herpes suppression trials.
Table 3 Selected Laboratory Abnormalities in Genital Herpes Suppression Studies * Parameter Famciclovir (n=660) † % Placebo (n=210) † % Anemia (<0.8 x NRL) 0.1 0.0 Leukopenia (<0.75 x NRL) 1.3 0.9 Neutropenia (<0.8 x NRL) 3.2 1.5 AST (SGOT) (>2 x NRH) 2.3 1.2 ALT (SGPT) (>2 x NRH) 3.2 1.5 Total Bilirubin (>1.5 x NRH) 1.9 1.2 Serum Creatinine (>1.5 x NRH) 0.2 0.3 Amylase (>1.5 x NRH) 1.5 1.9 Lipase (>1.5 x NRH) 4.9 4.7 * Percentage of patients with laboratory abnormalities that were increased or decreased from baseline and were outside of specified ranges.
† n values represent the minimum number of patients assessed for each laboratory parameter.
NRH=Normal Range High.
NRL=Normal Range Low.
HIV-infected patients In HIV-infected patients, the most frequently reported adverse events for famciclovir (500 mg twice daily; n=150) and acyclovir (400 mg, 5x/day; n=143), respectively, were headache (17% vs.
15%), nausea (11% vs.
13%), diarrhea (7% vs.
11%), vomiting (5% vs.
4%), fatigue (4% vs.
2%), and abdominal pain (3% vs.
6%).
6.2 Postmarketing Experience The adverse events listed below have been reported during post-approval use of famciclovir tablets.
Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Blood and lymphatic system disorders Thrombocytopenia Hepatobiliary disorders Abnormal liver function tests, cholestatic jaundice Immune system disorders Anaphylactic shock, anaphylactic reaction Nervous system disorders Dizziness, somnolence, seizure Psychiatric disorders Confusion (including delirium, disorientation, and confusional state occurring predominantly in the elderly), hallucinations Skin and subcutaneous tissue disorders Urticaria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema (e.g., face, eyelid, periorbital, and pharyngeal edema), hypersensitivity vasculitis C ardiac disorders Palpitations